Talphera Stock Price, News & Analysis
Company Description
Talphera (NASDAQ: tlph) is a publicly traded drug manufacturers - specialty & generic company in the Pharmaceutical Preparations sector. The company has a market capitalization of $37.4M, ranking #5,794 among all listed U.S. companies by market cap.
tlph stock has gained 46.7% over the past year. Shares last traded at $0.7777.
On a trailing twelve-month basis, Talphera reported revenue of $28K with net income of -$14.3M. The company operates at a net profit margin of -51035.7%.
This page provides a comprehensive overview of tlph stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Talphera (tlph) stock last traded at $0.7777, down 2.57% from the previous close. Over the past 12 months, the stock has gained 46.7%. At a market capitalization of $37.4M, tlph is classified as a micro-cap stock with approximately 50.0M shares outstanding.
Latest News
Talphera has 10 recent news articles. Of the recent coverage, 5 articles coincided with positive price movement and 5 with negative movement. Key topics include earnings, conferences, management, private placement, clinical trial. View all tlph news →
SEC Filings
Talphera has filed 5 recent SEC filings, including 1 Form 4, 1 Form EFFECT, 1 Form 424B7, 1 Form S-3. The most recent filing was submitted on April 2, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all tlph SEC filings →
Insider Radar
Insider buying activity at Talphera over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.
Financial Highlights
Talphera generated $28K in revenue over the trailing twelve months, operating income reached -$13.5M (-48157.1% operating margin), and net income was -$14.3M, reflecting a -51035.7% net profit margin. The company generated -$11.4M in operating cash flow. With a current ratio of 5.49, the balance sheet reflects a strong liquidity position.
Upcoming Events
Niyad PMA approval
PMA approval decision
Talphera has 2 upcoming scheduled events. The next event, "Niyad PMA approval", is scheduled for July 1, 2026 (in 90 days). Investors can track these dates to stay informed about potential catalysts that may affect the tlph stock price.
Short Interest History
Short interest in Talphera (tlph) currently stands at 1.1 million shares, down 4.2% from the previous reporting period, representing 3.2% of the float. Over the past 12 months, short interest has increased by 498.7%. This relatively low short interest suggests limited bearish sentiment. The 6.3 days to cover indicates moderate liquidity for short covering.
Days to Cover History
Days to cover for Talphera (tlph) currently stands at 6.3 days, up 6.4% from the previous period. This moderate days-to-cover ratio suggests reasonable liquidity for short covering, requiring about a week of average trading volume. The days to cover has increased 53.4% over the past year, indicating either rising short interest or declining trading volume. The ratio has shown significant volatility over the period, ranging from 1.0 to 10.6 days.
tlph Company Profile & Sector Positioning
Talphera (tlph) operates in the Drug Manufacturers - Specialty & Generic industry within the broader Pharmaceutical Preparations sector and is listed on the NASDAQ.
Investors comparing tlph often look at related companies in the same sector, including Aytu Biopharma Inc (AYTU), Gelteq Limited (GELS), Flora Growth Corp (FLGC), Therapeuticsmd Inc (TXMD), and Scynexis (SCYX). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate tlph's relative position within its industry.